How Does Confluent Stock Compare With Peers?
Confluent (CFLT) stock has experienced a notable decline, falling 11% over the past year. This underperformance raises questions about its standing against peers like Gen Digital (GEN), UiPath (PATH), SentinelOne (S), and Verint Systems (VRNT) in the dynamic real-time data streaming market. A closer look at Confluent reveals robust last twelve months (LTM) revenue growth of 21.6% and a positive free cash flow (FCF) margin of 2.8%. However, the company faces profitability hurdles, marked by a negative LTM operating margin and a negative price-to-earnings (PE) ratio, leading to valuation scrutiny when compared to more profitable rivals.
- Operating Margin: CFLT’s -34.7% operating margin, trailing GEN’s 37.9%, reflects aggressive spending to capture market share.
- Revenue Growth: CFLT’s 21.6% revenue growth, outpacing most peers, signals robust demand for its real-time data solutions, though S leads.
- Stock Performance: CFLT’s -11.3% stock decline and -22.5 PE signal investor skepticism regarding its path to profitability vs. PATH.
Here’s how Confluent stacks up across size, valuation, and profitability versus key peers.
| CFLT | GEN | PATH | S | VRNT | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 10.3 | 16.5 | 10.3 | 4.9 | 1.2 |
| Revenue ($ Bil) | 1.1 | 4.5 | 1.5 | 0.9 | 0.9 |
| PE Ratio | -22.5 | 30.7 | 340.3 | -14.1 | 20.1 |
| LTM Revenue Growth | 21.6% | 16.2% | 8.3% | 25.4% | -2.3% |
| LTM Operating Margin | -34.7% | 37.9% | -3.1% | -36.2% | 8.6% |
| LTM FCF Margin | 2.8% | 29.1% | 20.7% | 1.8% | 12.6% |
| 12M Market Return | -11.3% | -12.3% | 30.2% | -42.3% | -33.0% |
For more details on Confluent, read Buy or Sell CFLT Stock. Below we compare CFLT’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- What’s Behind Tilray’s 3.5X Surge?
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| CFLT | 21.6% | – | 24.0% | 32.6% | 51.1% |
| GEN | 16.2% | 3.6% | 14.6% | 18.6% | |
| PATH | 8.3% | 9.3% | 23.6% | 18.6% | |
| S | 25.4% | 32.2% | 47.1% | 106.1% | |
| VRNT | -2.3% | -0.1% | 0.9% | 3.2% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| CFLT | -34.7% | – | -43.5% | -57.1% | -79.0% |
| GEN | 37.9% | 41.2% | 30.7% | 38.4% | |
| PATH | -3.1% | -11.4% | -12.6% | -32.9% | |
| S | -36.2% | -40.1% | -59.8% | -95.4% | |
| VRNT | 8.6% | 11.7% | 7.6% | 6.4% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| CFLT | -22.5 | – | -26.1 | -15.9 | -13.8 |
| GEN | 30.7 | 26.3 | 23.9 | 9.9 | |
| PATH | 340.3 | -96.6 | -155.8 | -21.2 | |
| S | -14.1 | -24.2 | -23.9 | -10.7 | |
| VRNT | 20.1 | 20.7 | 44.8 | 159.1 |
Still not sure about CFLT stock? Consider portfolio approach.
Multi Asset Portfolios Offer More Upside With Less Risk
Individual picks are volatile but diversified assets offset each other. A multi asset portfolio helps you stay the course capture upside and reduce downside.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices